Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
32 Dulaglutide in the REWIND study and exenatide in the DURATION study improved both BP and lipid profiles in patients with T2D
These effects may lead to a decrease in triglyceride levels for some individuals
However, it increased 1.8 fold, 1.9 fold and 2.1 fold, respectively in GSH treated plants
Notably, DPP-IV targets include cytokines, growth factors, and neurotransmitters, in addition to islet-derived peptide hormones, indicating that the improvements in beta-cell function in response to DPP-IV inhibition may also be mediated by other intra-islet paracrine signaling factors
US$ 28.10
US$ 20.04
US$ 21.95
US$ 20.69
US$ 23.21
US$ 23.24
